Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
Prostate cancer is the most common malignancy among men in the United States and Canada.
Suspicion of prostate cancer with modern screening tests, such as digital rectal exam (DRE)
and prostate serum antigen (PSA) require ultrasound-guided biopsy for pathological
diagnosis. However, this technique misses cancer in nearly one quarter of patients and finds
clinically insignificant disease in another third of patients, resulting in over-treatment
and unnecessary morbidity.
MRI is the best imaging method for prostate cancer detection, but current techniques cannot
reliably predict tumour grade and are often unreliable for localizing cancer, particularly
within the transition zone, where specificity is low. The primary objective of this pilot
study is to evaluate the added benefit of localizing prostate cancer and predicting tumour
grade with Hyperpolarized 13C MRI, in addition to traditional T2-weighted and
diffusion-weighted MR imaging.
The investigators propose a pilot study, in men diagnosed with prostate cancer awaiting
prostatectomy, with the specific goals of comparing pre-operative imaging findings to ground
truth histology, using whole-mount prostate specimens. The results of this study will
provide insight into the prostate cancer disease signatures with MRI and determine if there
is added benefit for incorporation of this new technique into future clinical MRI protocols.
If future imaging tests could determine the size, grade and extent of disease, this would
open the door for less invasive, localized treatment options with reduced morbidity.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society